Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 52535 [2013-20531]
Download as PDF
<![CDATA[
52535
Federal Register / Vol. 78, No. 164 / Friday, August 23, 2013 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Type of respondents
Form No. and name
Medical/Clinical Laboratory Technologist ......
Staff RN .........................................................
57.305: Hemovigilance Incident ....................
57.400: Outpatient Procedure Component—
Annual Facility Survey.
57.401: Outpatient Procedure Component—
Monthly Reporting Plan.
57.402: Outpatient Procedure Component
Event.
57.403: Outpatient Procedure Component—
Monthly Denominators and Summary.
57.500: Outpatient Dialysis Center Practices
Survey.
57.501: Dialysis Monthly Reporting Plan ......
57.502: Dialysis Event ..................................
57.503: Denominator for Outpatient Dialysis
57.504: Prevention Process Measures
Monthly Monitoring for Dialysis.
57.505: Dialysis Patient Influenza Vaccination.
57.506: Dialysis Patient Influenza Vaccination Denominator.
57.600: State Health Department Validation
Record.
Staff RN .........................................................
Staff RN .........................................................
Staff RN .........................................................
Registered Nurse (Infection Preventionist) ....
Staff
Staff
Staff
Staff
RN
RN
RN
RN
.........................................................
.........................................................
.........................................................
.........................................................
Staff RN .........................................................
Staff RN .........................................................
Epidemiologist ................................................
Kimberly S. Lane,
Deputy Director, Office of Scientific Integrity,
Office of the Associate Director for Science,
Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2013–20609 Filed 8–22–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
tkelley on DSK3SPTVN1PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns Impact of Japanese
Encephalitis Vaccination in Cambodia,
Funding Opportunity Announcement
(FOA) CK14–001, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 1:00 p.m.–3:00 p.m.,
October 17, 2013 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters To Be Discussed: The meeting
will include the initial review,
VerDate Mar<15>2010
18:43 Aug 22, 2013
Jkt 229001
discussion, and evaluation of
applications received in response to
‘‘Impact of Japanese Encephalitis
Vaccination in Cambodia, FOA CK14–
001’’.
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road NE., Mailstop E60, Atlanta,
Georgia 30333, Telephone: (404) 718–
8833.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2013–20531 Filed 8–22–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0002]
Withdrawal of Approval of New Animal
Drug Applications; Quali-Tech
Products, Inc.; Bambermycins;
Pyrantel; Tylosin; Virginiamycin
AGENCY:
Food and Drug Administration,
HHS.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average burden
per response
(in hrs.)
500
5,000
12
1
10/60
5/60
5,000
12
15/60
5,000
25
40/60
5,000
12
40/60
6,000
1
6,000
6,000
6,000
600
12
60
12
12
5/60
13/60
6/60
30/60
250
75
10/60
250
5
10/60
152
50
15/60
ACTION:
1.75
Notice.
The Food and Drug
Administration (FDA) is withdrawing
approval of four new animal drug
applications (NADAs) held by QualiTech Products, Inc., at the sponsor’s
request because the products are no
longer manufactured or marketed.
DATES: Withdrawal of approval is
effective September 3, 2013.
FOR FURTHER INFORMATION CONTACT:
David Alterman, Center for Veterinary
Medicine (HFV–212), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855; 240–453–6843;
email: david.alterman@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: QualiTech Products, Inc., has requested that
FDA withdraw approval of the
following four NADAs because the
products, used to manufacture Type C
medicated feeds, are no longer
manufactured or marketed: NADA 097–
980 for Quali-Tech TYLAN–10 (tylosin
phosphate) Premix, NADA 118–815 for
Q.T. BAN–TECH (pyrantel tartrate),
NADA 132–705 for FLAVOMYCIN
(bambermycins), and NADA 133–335
for STAFAC (virginiamycin) Swine Pak
10.
Therefore, under authority delegated
to the Commissioner of Food and Drugs
and redelegated to the Center for
Veterinary Medicine, and in accordance
with § 514.116 Notice of withdrawal of
approval of application (21 CFR
514.116), notice is given that approval
of NADAs 097–980, 118–815, 132–705,
and 133–335, and all supplements and
SUMMARY:
E:\FR\FM\23AUN1.SGM
23AUN1
]]>Agencies
[Federal Register Volume 78, Number 164 (Friday, August 23, 2013)]
[Notices]
[Page 52535]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-20531]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns Impact of Japanese
Encephalitis Vaccination in Cambodia, Funding Opportunity Announcement
(FOA) CK14-001, initial review.
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting:
Time and Date: 1:00 p.m.-3:00 p.m., October 17, 2013 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Impact of Japanese Encephalitis Vaccination in Cambodia, FOA CK14-
001''.
Contact Person for More Information: Gregory Anderson, M.S.,
M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop
E60, Atlanta, Georgia 30333, Telephone: (404) 718-8833.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2013-20531 Filed 8-22-13; 8:45 am]
BILLING CODE 4163-18-P
